Dementia foundations and person-centered support
Dementia Medications: Different Diseases, Different Treatment Questions
By KindredMind Editorial Team
There is no single category of medicine that treats every cause of dementia. Medication decisions depend on the underlying disease, symptoms, other health conditions, treatment goals and the person's preferences. Qualified clinicians should make those decisions with the person and their appropriate supports. This guide does not recommend a medicine, give doses or tell anyone to start, stop or change treatment.
Separate four different conversations
Swipe within the table to reach every column. Keyboard users can focus the table area and use the arrow keys.
| Treatment question | Examples or category | Essential boundary |
|---|---|---|
| Symptoms affecting cognition or daily function | Cholinesterase inhibitors and memantine in selected circumstances | The underlying disease and current prescribing information determine appropriate use |
| Alzheimer's disease processes | Selected anti-amyloid therapies | Not treatments for dementia generally; eligibility and monitoring are specialized |
| Associated symptoms | Individualized treatment of depression, sleep problems or severe distress | Investigate contributors and non-drug support; benefits and harms differ |
| Medicines that may worsen confusion | Review of anticholinergic burden, sedating medicines and interactions | A medication review is not an instruction to stop a prescribed medicine |
The Alzheimer's Association separates cognitive treatments from medicines for associated symptoms. A medicine's use for one disease should not be generalized to another. [1]
Medicines used for cognitive symptoms
Donepezil, rivastigmine and galantamine are cholinesterase inhibitors. Memantine acts through a different mechanism. These medicines have particular indications and safety considerations; they are not interchangeable and do not cure dementia. The relevant diagnosis, stage, other medicines, potential side effects and agreed goals all matter. [1]
Ask what improvement or stability the clinician hopes to assess, how adverse effects will be recognized and when treatment will be reviewed. Do not infer that a medicine is appropriate simply because another family uses it. Alzheimer's disease, Lewy body dementia, vascular dementia and FTD require distinct clinical consideration.
Alzheimer's-specific disease-modifying treatments
Lecanemab (Leqembi) and donanemab (Kisunla) are anti-amyloid treatments with U.S. FDA approvals for Alzheimer's disease. Their labels describe starting treatment in the mild cognitive impairment or mild dementia stage of Alzheimer's disease, with confirmation of amyloid pathology. They are not approved treatments for all causes of MCI or all dementias, and they do not restore lost abilities or cure Alzheimer's. [2][3]
These treatments can cause amyloid-related imaging abnormalities (ARIA), including brain swelling or bleeding. Serious and fatal events can occur. Specialist assessment, discussion of genetic and other risk factors, MRI monitoring and review of other medicines are important parts of their prescribing requirements. This page does not provide a dosing or monitoring schedule. The current label and treating specialist govern those details. [2][3]
Canada is a separate approval context. Health Canada's Leqembi decision describes conditional authorization with eligibility restricted to APOE ε4 noncarriers or heterozygotes and confirmed amyloid pathology. Its Kisunla decision also restricts the indicated population to APOE ε4 noncarriers or heterozygotes with early Alzheimer's disease and confirmed amyloid pathology. U.S. and Canadian labels must not be treated as identical. Authorization does not by itself establish local availability, public coverage or an individual's eligibility. [4][5]
Approval and safety statements were checked against the linked FDA label sources and Health Canada decisions during preview preparation on November 10, 2026. Every named medicine and approval statement must be reverified against current official information immediately before publication. This is not a complete formulary.
Associated symptoms need their own assessment
Pain, infection, depression, sleep disruption, sensory difficulty and medication effects can contribute to a change in functioning or distress. Treating the cause may be different from prescribing for the visible behavior. Non-drug support should reflect the person's routines, environment and preferences.
Some medicines used for severe associated symptoms have substantial risks. Antipsychotics carry serious warnings in older adults with dementia-related psychosis, and people with Lewy body dementia can have particular sensitivity. A specialist discussion is not replaced by a list of drug names. [1]
Prepare for a medication review
- Bring the complete prescription, over-the-counter and supplement list.
- Describe the change and its timing, including recent additions or changes.
- Ask which condition and goal each medicine addresses.
- Ask how benefit, side effects and interactions will be reviewed.
- Ask whom to contact about a concern and what needs urgent help.
Do not independently stop a medicine because it appears on a “confusion” list. Abrupt changes can also cause harm. Sudden confusion needs prompt assessment; see delirium versus dementia. Person-centered care includes the person's priorities and informed participation, not a universal medication plan.
